Quantcast

Latest rheumatoid arthritis Stories

2014-10-22 12:30:14

Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA, Oct. 22, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring several data presentations on Cimzia(®) (certolizumab pegol) at the American College of Gastroenterology's (ACG) 2014 Annual Scientific Meeting in Philadelphia,...

2014-10-21 23:15:35

Ongoing and Recent Evidence Shows RA Patients Who Supplement Methotrexate With Folate Therapy Have Better Outcomes, According To Makers of EnLyte With Delta Folate. Sunset, LA (PRWEB) October 21, 2014 Over one million people in the U.S. suffer from rheumatoid arthritis (RA), an autoimmune disease marked by pain, swelling, and stiffness in the joints. The most common first line treatment for RA is methotrexate, a prescription medication belonging to the class of drugs knows as DMARDS....

2014-10-20 12:30:16

DALLAS, October 20, 2014 /PRNewswire/ -- ReportsnReports.com adds Gouty Arthritis (Gout) - Pipeline Review, H2 2014 market research report as well as EpiCast Report: Gout - Epidemiology Forecast to 2023 to the pharmaceuticals segment of its online library. The Gouty Arthritis (Gout) - Pipeline Review, H2 2014 [http://www.reportsnreports.com/reports/311359-gouty-arthritis-gout-pipeline-review-h2-2014.html ] market research report provides comprehensive information on...

2014-10-17 23:02:09

A California man filed a class action lawsuit against Immunex and Caremark CVS alleging that the pharmacy fails to properly refrigerate best-selling drug Enbrel when filling a mail order Caremark prescription. As a result, thousands of seniors and disabled persons may be using Enbrel that, based on the manufacturer’s own guidelines, should not be used and should be discarded immediately; the plaintiff further alleges that the unapproved Enbrel is ineffective in treating his arthritis...

2014-10-13 08:27:39

- HS is a painful, chronic inflammatory skin disease that impacts approximately 1 percent of the adult population worldwide with no approved treatment options available[1],[2],[3] AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-10-13 08:27:34

Be Joint Smart to educate roughly 28,000 local residents with PsA about their disease PORTLAND, Ore., Oct. 13, 2014 /PRNewswire-USNewswire/ -- If you're one of the roughly 28,000 Seattle metro residents struggling with pain from psoriatic arthritis (PsA)--an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons--learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation, at...

2014-10-08 16:23:50

Be Joint Smart to educate roughly 23,200 local residents with PsA about their disease PORTLAND, Ore., Oct. 8, 2014 /PRNewswire-USNewswire/ -- If you're one of the roughly 23,200 San Diego metro residents struggling with pain from psoriatic arthritis (PsA)--an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons--learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation,...

2014-10-08 12:28:53

Patient Shares For Newer Alternative MOA Agents Are Also Expected To Grow In The Next Six Months, According To Findings From Decision Resources Group BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that despite the increasing percentage of rheumatoid arthritis (RA) patients treated with agents with a newer mechanism of action (MOA), three-quarters of DMARD-failure RA patients who are naive to biologics/Pfizer's Xeljanz are still initiated on tumor necrosis...

2014-10-07 12:28:28

Physicians Indicate that Switching of Currently Treated Patients to Biosimilar Infliximab Is Likely to be Limited, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed rheumatologists in France, Germany and the United States expect to prescribe biosimilar infliximab within one year of launch if the biosimilar is priced at a net discount of 15-30 percent to Remicade and has demonstrated...

2014-10-06 12:28:55

Medac Pharma Brings Rasuvo From U.S. Concept to Launch in One Year ­­CHICAGO, Oct. 6, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo(TM) (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S. Rasuvo is a single dose, subcutaneous methotrexate (MTX) auto injector offering the widest dose range in a...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related